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It is not easy to study these questions with normal tissues for technical reasons, one of which is that the number of factors is always high. With tumours the number varies, but may be low, and in addition tumours stimulate a better antibody response.
Iso-immune reactions are most easily studied in the erythrocytes, and it so happens that certain important iso-antigens in Strong's A strain of mice are shared by the erythrocytes and fixed tissues. The same is true of certain other strains, but the A strain is the easiest to work with. Four tumours from this strain have been studied genetically and serologically.
The first two were studied in England; in both it appeared that two histocompatibility genes were concerned, one of which was identical with a gene for an antigen known as antigen II. By serological means it was shown that the tumours contained another antigen in addition to 11. Occasionally iso-antibodies were formed against it, but too irregularly 4nd at too low a titre to be of value for genetical work (Gorer, 1937 (Gorer, , 1938 (Gorer, , 1942 (Browning, 1947) and induced tumours (Gorer, unpublished) are more susceptible to bacterial infection than are normal animals. One needs a great deal more information on this point, using pregnant animals, and animals with grafts of embryonic tissues as controls. This may turn out to be an important property of malignant growths. At present the bulk of expert opinion is against invoking any direct toxic effect of tumours to account for the illness one observes in human cancer. This is quite logical. There are numerous reasons why a cancer patient should be ill. However, work with transplanted tumours suggests that the subject cannot be considered closed. SUMMARY. 1. Tumour transplantation was used to show the antigenic basis of transplantation immunity in general.
2. One of the pertinent histocompatibility genes has been shown to be closely linked to the gene for a tail anomaly in mice.
3. It is believed that all mammals (and perhaps many other forms) are highly polymorphic for histocompatibility genes. There is evidence that some of these genes have a high mutation rate in mice. The possible significance of this is discussed in the text.
4. Serological studies show that tumours may kill an animal in spite of antigenic differences. Some antigens are weak, and rarely elicit an effective defensive reaction. Genetic studies on transplantation are therefore not a completely accurate indication of antigenic structure.
5. Tumours undergo some antigenic simplification during transplantation. Probably one or two antigens increase in amount and crowd out the others.
6. Malignant tumours appear to exert a depressive action on the defences of the host. 
